Showing results (1-10 of 257) with videos related to
Sort By:
Pageof 26
Pituitary|October 15, 2014
Pituitary image: pituicytomaClaudia Teti, Lara Castelletti, Luca Allegretti, et al.Reviews in Endocrine & Metabolic Disorders|July 26, 2019
Current perspectives on the impact of clinical disease and biochemical control on comorbidities and quality of life in acromegalyFederico Gatto, Claudia Campana, Francesco Cocchiara, et al.Therapeutics and Clinical Risk Management|May 23, 2020
Octreotide-Resistant Acromegaly: Challenges and SolutionsGiuliana Corica, Marco Ceraudo, Claudia Campana, et al.The Journal of Clinical Endocrinology and Metabolism|November 25, 2020
Discordant GH and IGF-1 Results in Treated Acromegaly: Impact of GH Cutoffs and Mean Values AssessmentClaudia Campana, Francesco Cocchiara, Giuliana Corica, et al.Pituitary|November 10, 2021
Evaluation of acromegaly treatment direct costs with respect to biochemical control and follow-up lengthFrancesco Cocchiara, Claudia Campana, Federica Nista, et al.Journal of Pediatric Endocrinology & Metabolism : JPEM|May 17, 2006
Management of cystic craniopharyngiomas in childhood by a transsphenoidal approachGianluigi Zona, Renato SpaziantePituitary|November 19, 2010
In vivo and in vitro response to octreotide LAR in a TSH-secreting adenoma: characterization of somatostatin receptor expression and role of subtype 5Federico Gatto, Federica Barbieri, Lara Castelletti, et al.Endocrine|May 19, 2015
Impact of pre-treatment with somatostatin analogs on surgical management of acromegalic patients referred to a single centerSusanna Bacigaluppi, Federico Gatto, Pasquale Anania, et al.Pituitary|October 20, 2014
Clinical outcome and evidence of high rate post-surgical anterior hypopituitarism in a cohort of TSH-secreting adenoma patients: Might somatostatin analogs have a role as first-line therapy?Federico Gatto, Ludovica F Grasso, Elena Nazzari, et al.Pageof 26